Study Participants Wanted

Note: Only studies being conducted by the UMass Department of Psychiatry will be listed here. No other entries accepted.

Members of the department wishing to submit information like this should use the format below, include a subject line of “Study Participants Wanted,” and email it to psychiatrycommunications@umassmed.edu.

Investigational Drug Study for Adolescents with Schizophrenia

What are we studying?
The purpose of the study is to evaluate whether NaBen (Sodium Benzoate) is an effective add-on treatment for adolescents with schizophrenia

Who can participate?
Adolescents between 12 and 17 years of age who have a diagnosis schizophrenia. Participants need to be on a stable antipsychotic treatment for their schizophrenia and still be experiencing residual symptoms.

How will participants be compensated?
Compensation will be provided for time and travel.

For more information, contact CANDI at (774) 455-4100

Docket # H00005591


Research Study: A Study to Assess the Janssen Autism Knowledge Engine (JAKE™) in Children and Adults with Autism Spectrum Disorder and in a Typically Developing Cohort

If you or your child has been diagnosed with ASD (Autism Spectrum Disorder), Then the JAKE™ System Clinical Trial Study may be of interest to you.

This study is being conducted in order to develop a system that helps to measure physical and behavioral outcomes of people with Autism Spectrum Disorder (ASD).

The main goal of this study is to evaluate the usability of the JAKE™ (Janssen Autism Knowledge Engine) as a system to monitor clinical outcomes in ASD.
This study is noninvasive, and you or your child will continue taking his or her prescribed or non-prescribed ASD treatment and therapies during this study.
The total study duration for each study participant (you and your child) will last for approximately 8 weeks.
Compensation for time and travel will be provided.

Criteria: Children (aged 6 and older) and adults both with and without autism.

Please contact us to learn more about this study: Please contact CANDI at 774-455-4100 or email at ChildResearch@umassmed.edu.
This is study is sponsored by Janssen Research Development, LLC

Docket # H00008176


Understanding Clinical Trials Study 

The goal of this study is to  improve patients’ understanding of participating in clinical trials for illnesses such as depression. We are recruiting individuals who are currently being treated for depression and are willing to spare 30-45 minutes of their time to view a brief presentation on a laptop. You would not be asked to participate in a real clinical trial – only to view a presentation and complete a very brief, confidential survey, at a time and place that’s convenient for you. 

We can offer you $20.00 in appreciation for your help. Please note that your decision about whether or not to participate is completely up to you and will not affect any of the clinical services you may be receiving. 

If you are interested in learning more about this project and determining if you are eligible to participate, please contact Karen Albert at Karen.Albert@umassmed.edu or 508-856-8725.

UMMS IRB# H00004365


Transition-age Youth Psychotherapy Experiences (TYPE) Study
UMass Medical School Transitions RTC Research Study for Young Adults (Ages 18-25)

The UMass Transitions Research and Training Center (RTC) is currently recruiting for a research study to better understand the experiences, both good and bad, of young adults who are participating in outpatient psychotherapy treatment.

We are seeking:
Young adults between the ages of 18-25 who have a self-identified mental health condition and who are beginning outpatient psychotherapy or have been involved in outpatient psychotherapy for less than one year.

Participation includes:
2 interviews, scheduled 2 months apart, at a location of the participant's choice. The interviews involve the completion of an online survey and a qualitative interview portion. Participants will receive a $25 gift card for each interview completed. Each participant can earn up to $50 for taking part in the study.

Please email, call, or text to learn more about the study and have all your questions answered:
Laura Golden
Call or text: 774-437-2124
Laura.Golden@UMassMed.edu

IRB# H00007759


Collecting Histories of Education and Employment During Recovery
UMass Medical School Transitions RTC Research Study for young adults (aged 26-30)

The UMass Transitions Research and Training Center (RTC) is currently recruiting for a research study to better understand the employment and education experiences of young adults.


We are seeking:
Young adults between the ages of 26-30 who have a history of a mental health condition including one of the following:

  • Inpatient hospitalization
  • "Day program" treatment
  • Client of DMH
  • Formal special education services
  • Formal medical leave of absence from school or work

We are also looking to include young parents who meet the above criteria.

Participation includes a one-time, 1.5-hour interview at a location of their choice. Participants will receive a $30 gift card for their time.

To learn more please call or text Peter Bui or Laura Golden at 774-502-7813, e-mail us at Peter.Bui@UMassmed.edu or Laura.Golden@UMassmed.edu, or visit us at http://www.voices4hope.net/cheer-study.html

IRB# H00008523


Postpartum Depression: 60-hour Investigational Treatment Related to Hormones

Feeling overwhelmed or irritable?
Feeling down or blue?
Having crying episodes?

Depression during pregnancy and after giving birth is common.

This research will find out if an investigational drug related to a natural substance that your body makes, especially during pregnancy, treats postpartum depression.

  • This is a one-month study including 4 study visits at UMass Medical School/UMass Medical Center.
  • The investigational treatment or placebo is given for 60 hours only.
  • The investigational treatment can be given in addition to other medications, including antidepressants, women may already be taking.
  • Adult women who delivered a baby within the last 6 months and are experiencing symptoms of sadness and/or anxiety may participate.

Cash compensation as well as childcare & transportation compensation is provided.

To learn more please call Dr. Kristina Deligiannidis (774-455-4134).

Docket#H-00009521.


Outpatient Couple Therapy for Service Members and Veterans with Alcohol-Related Concerns

The Alcohol Behavioral Couple Therapy Military treatment research program is specifically designed to help service members or veterans and their partners to learn skills that will help to reduce drinking and to improve relationship functioning.

The program will include a thorough assessment, 15 weekly outpatient couple therapy sessions (free of charge), and a follow-up session.  Compensation will be provided for the intake and follow-up sessions.

Below are the major inclusion criteria:

  • Be a service member or veteran of the U.S. Military (all branches welcome including National Guard and Reserves)
  • Have a drinking habit you want to change
  • Be 18 or older
  • Be married or in a committed relationship

For more information, please contact Rachel Rosen (508-856-8745) or Dr. Beth Epstein (732-995-7315).

IRB# H-3823


12-week CBT and Self-Regulation Psychotherapy Group Treatment for Co-morbid Pain and Opioid Abuse

The goal of this study is to help participants simultaneously develop better pain management skills and reduce drug abuse. Our intervention may help reduce drug use and improve pain management.

This is a 15 visit study and participants are compensated for three assessment visits after completing the study.

Below are the major inclusion criteria:

  • Be between 18 and 65 years old
  • Have a history of co-morbid opioid addiction and chronic pain
  • Be on ONE of the following for opioid maintenance:
    • Methadone
    • Buprenorphine (Suboxone)

For more information contact Dr. Amy Wachholtz (508-334-2164).

IRB# H-14337


The Early Treatment Study

The goal of this study is to compare the standard treatment for psychosis with a treatment version of the medication aripiprazole that is taken only once each month. Study participants at this study location will receive the care your center usually provides. Those who qualify will receive study-related medical exams, and lab tests at no charge. People in this study will be compensated for their time. In order to participate in the study, individuals must be evaluated by a study doctor and meet certain criteria including, but not limited to:

  • male or female aged 18-35
  • have a clinical diagnosis of psychosis and up to 5 years of antipsychotic medication exposure

For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.

Funding Source: Vanguard Research Group

IRB Docket#H00007426


Tardive Dyskinesia Study

We invite those who are experiencing involuntary movements in their face or other parts of their body – and suffer from schizophrenia, schizoaffective disorder – to see if they may qualify for the Kinect 3 Study. The purpose of this clinical research study is to evaluate the effectiveness, safety, and tolerability of an investigational oral medication for tardive dyskinesia. Those who qualify will receive study medication, study-related medical exams, and lab tests at no charge. In order to participate in the study, individuals must be evaluated by a study doctor and meet certain criteria including, but not limited to:

  • male or female aged 18 to 85 years
  • have clinical diagnosis of schizophrenia or schizoaffective disorder
  • have a clinical diagnosis of Tardive Dyskinesia (TD)

For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.

IRB Docket#H00006334


Mood Disorder, Trauma, and the Brain

Mood Disorder, Trauma, and the Brain is a Brain Imaging Research Study for Children between the ages of 8 and 12, with a Mood Disorder or those who are Typically Developing.

We are looking for:

  • 4 more subjects with a mood disorder
  • 3 more subjects with a mood disorder and a history of trauma
  • 2 more subjects who are typically developing

For more information about the study, please visit our website at www.umassmed.edu/psychiatry/candi, call us at 774-455-4100, or email us at ChildResearch@umassmed.edu.

IRB Docket # H00001011


GeneSight Clinical Study

The study is trying to see if a genetic test (called GeneSight®) is helpful in guiding clinicians’ selection of medications for depression.

You might be eligible to participate in this study if:

  • You are trying or have recently tried a psychiatric medication, and
  • Your symptoms of depression are not improving despite at least 6 weeks on the treatment you are receiving, and/or
  • You are unable to tolerate the medication and have discontinued it.

If you would like more information, please call Jessica 774-455-4045.

IRB Docket # H-00004690


A Psychotic Disorders Program Research Study

Exenatide weekly injection as an adjunctive treatment in patients with schizophrenia

Have you been diagnosed with Schizophrenia or Schizoaffective disorder? Are you interested in helping us learn if a drug called Exenatide may improve your memory and thinking?

If so, you may be eligible to participate in a research study at UMass Medical School. Studies suggest that Exenatide (an FDA-approved drug) can reduce inflammation, which may protect the brain and improve memory and thinking in individuals with schizophrenia or schizoaffective disorder. Your participation in the study will last 24 weeks (6 months).

You will be compensated (paid) for your time. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.

Funding Source: Stanley Medical Research Institute
IRB Docket# H00004119


Vitamin D Supplementation and Bipolar Depression

Bipolar depression is well known to be difficult to treat. Many of the medications used can have unpleasant side effects. Finding a well tolerated and safe option that would decrease symptoms of depression in bipolar disorder would help many people. Vitamin D is often low in people with depression, including bipolar depression. Vitamin D supplementation has been shown in many studies to help reduce depression symptoms in people with non-bipolar depression.

The goal of this research is to see if Vitamin D supplementation in people with bipolar disorder is associated with improved mood, in particular less depression.

This study will monitor mood symptoms and Vitamin D levels over the course of 12 weeks.

Participants are:

  • 25-70 years old
  • Diagnosed with bipolar disorder
  • Currently feeling down, sad, or depressed
  • Low Vitamin D levels (evaluated by blood work at first study visit)

Participants will receive financial compensation as well study-related evaluations at no cost.

For more information, please contact the research study coordinator Jessica Penny at 508-334-7352 or Principal Investigator Wendy Marsh, M.D. at 508-856-5071.

Docket # H00000800


A Research Study on Treatment of Marijuana Use and Schizophrenia

The UMass Psychotic Disorders Research Program is running a NIH-funded study on marijuana abuse and schizophrenia.

People who have schizophrenia often abuse marijuana. We are studying whether an FDA approved Clozapine can reduce marijuana use.

The study last about 14 weeks and involves:

  • Weekly meetings with the research staff
  • Answering questions about substance use and current symptoms
  • Half the people in the study will get a medicine called “clozapine” and the other half will get a medicine called “risperidone”.

People in the study will not know which type of pill they are getting.

We are looking for people who:

  • Have been told they have schizophrenia
  • Are willing to take medicine for schizophrenia
  • Use marijuana regularly
  • Are ages 18-55

People in the study will be compensated for their time. All information is kept private.
For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu

Docket # H-00001171


The Psychotic Disorders Program at UMass Medical School is happy to share with you a NIH-funded study entitled Salsalate as an Adjunctive Treatment in Patients with Schizophrenia.

This is an open-label 12-week pilot research study examining how salsalate, an anti-inflammatory drug affects positive and negative symptoms of schizophrenia, Hemoglobin A1c, fasting glucose, other metabolic issues and cognitive functioning when added to an antipsychotic medication. We are seeking your help to recruit eligible subjects.

Inclusion Criteria

  • M/F, Age 18-65 years
  • Diagnosis of schizophrenia or schizoaffective disorder
  • Currently on a stable dose of antipsychotic medication (for at least one month)

Exclusion Criteria

  • Current substance abuse
  • Significant medical illnesses including uncontrolled hypertension, diabetes, seizure disorder, severe cardiovascular, cerebrovascular, pulmonary or thyroid diseases.
  • Currently on immunosuppressant medication including oral steroids. 
  • Use of anti-coagulants. 

Subjects will be compensated for their time.

For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.
Docket # H-14814


Research Study Needs Male Participants With ADHD

Young men with ADHD are needed for a research study looking at brain function. Participants may qualify if:

  • They are between 14 -24 years old
  • They have ADHD
  • They are right-handed

We need both smokers and non-smokers for this study, so tobacco smokers are encouraged to apply! Participants will complete questionnaires and have 1 non-invasive MRI imaging scan. Compensation (up to $130) will be provided.

If you are interested in participating, or would like more information, please contact us:

Phone: 508-856-8185
Email:
CCNI.Research@umassmed.edu

UMass Medical School
UMMS IRB Docket # H-14119


National Institute of Mental Health (NIMH)
Sustaining Remission of Psychotic Depression Study

Patients that are currently suffering from depression with irrational worries are invited to participate in a research study to determine how long people need to stay on an antipsychotic medication after they recover from their symptoms. Study participation will last up to 20 weeks and patients will receive a combination of an antipsychotic medication and an antidepressant medication. Patients must be:

  • 18 to 85 years of age 
  • experiencing symptoms of depression with irrational worries 
  • not be pregnant 

Patients will receive study medication and study-related care at no cost. Qualifying patients will be eligible to participate in 9-month follow-up study. Compensation provided.

Contact Jessica Penny @ 508-334-7352

Docket # H-14207


The UMass Psychotic Disorders Research Program is running an NIH-funded study to investigate whether the combination of risperidone and desipramine is effective in reducing alcohol consumption in individuals suffering from schizophrenia and ongoing alcohol drinking. Below are the major inclusion and exclusion criteria:

Inclusion criteria: Age 18-65; Suffers from schizophrenia or schizoaffective disorder; Meets diagnostic criteria for current alcohol abuse or dependence

Exclusion Criteria: Suffers from any substance abuse disorder other than caffeine, nicotine, and cannabinoid containing substances; Continues to use alcohol despite treatment with medications such as naltrexone, acamprosate, disulfiram, topiramate, etc.

For more information contact Dr. Xiaoduo Fan (508-856-3881), or Dr. Amy Harrington (508-860-1260).

Docket #H-14857


Brain Imaging: A Research Study for Boys with an Autism Spectrum Disorder or Typical Development

  • Males between 13 & 17 years of age.
  • Typically Developing or with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder NOS

Participants will receive a MRI scan, a brief neurocognitive evaluation and interview with one or more clinicians.

Compensation will be provided for time and travel.

Contact: The Child & Adolescent NeuroDevelopment Initiative (CANDI).
Phone: 508-856-5896 or E-mail: ChildResearch@umassmed.edu.
Visit us on the web at: http://www.umassmed.edu/psychiatry/candi/index.aspx

Docket # H-14247


Investigational Drug Study for Adolescents and Adults with Fragile X Syndrome

Males or females between 16 and 50 years of age with a diagnosis of Fragile X Syndrome.

Eligible participants will receive up to approximately 3 months of investigational drug in the study. During the study, participants will be monitored for side effects and will meet with the study doctor every 3 weeks. Between office visits, caregivers, parents, or guardians will also receive phone calls from the study doctor. At the end of the study, the investigational drug will be gradually withdrawn over a 3-week period. This study will last up to approximately 4 1/2 months and requires up to 8 visits to the University of Massachusetts Medical School and 10 phone calls with the study doctor.
For each visit to the office, a small payment will be offered to offset travel expenses. The investigational drug and all study-related evaluations are provided at no cost.

Contact: The Child & Adolescent NeuroDevelopment Initiative (CANDI).
Phone: 508-856-5896 or email ChildResearch@umassmed.edu.
Visit us on the web at: http://www.umassmed.edu/psychiatry/candi/index.aspx

Docket# H•14789


Hormones and the Brain: A Research Study for Girls with Bipolar Disorder or Typical Development

Females 6-16 years old and right-handed.

Participants will be part of a brain imaging research study to evaluate the influence of certain hormones on the development of the central nervous system.

Compensation will be provided for time and travel.

Contact: The Child & Adolescent NeuroDevelopment Initiative (CANDI).
Phone: 508-856-5896 or email ChildResearch@umassmed.edu.
Visit us on the web at: http://www.umassmed.edu/psychiatry/candi/index.aspx

Docket# 13692


ADHD Study

Men aged 14 – 24.

Participants must be diagnosed with ADHD and be right-handed.

Participants will be asked to fill out surveys and undergo a non-invasive MRI scan. No medication is given for this study.

Compensation will be provided for time and travel.
Contact: 508-856-8185 or email CCNI.Research@umassmed.edu.

Docket H-14119


Does Your Child Experience Mood Swings OR Have a Diagnosis of Bipolar Disorder?

Children aged 8 – 17.

Participants MUST Have a diagnosis of Bipolar Disorder OR Experience mood swings AND have a parent with Bipolar Disorder.
Participants will undergo two non-invasive MRI scans, cognitive testing, and take a daily Vitamin D Supplement.

Compensation for time and travel will be provided.

Contact: 508-856-5896 or email us at ChildResearch@umassmed.edu.

UMMS Docket H-13821


Center for Psychopharmacologic Research and Treatment (CPRT)

Hormones in Pregnancy and Brain Imaging in Postpartum Depression Research Study

This NIH-funded study will monitor for symptoms of depression and anxiety during late pregnancy (2 visits) and after giving birth (3 visits). We also monitor blood hormone levels (each visit) and in the postpartum, participants will have one brain MRI scan done. Total participation is about 4-7 hours.
Participants in this study:

  • are 18-40 years old and pregnant 
  • are either: healthy without mood symptoms OR have some symptoms of depression or anxiety/stress 
  • plan to give birth at UMass Memorial Medical Center 
  • are not taking an antidepressant or steroid medication 

Participants will receive financial compensation as well study-related evaluations at no cost. Participants who complete the MRI brain scan will also receive a picture of their brain MRI scan.

To learn more, please contact the study doctor, Kristina M. Deligiannidis, M.D. @ 508-856-5928.

Docket # H-00001214


BROADENTM Study for Major Depressive Disorder

  • For participants aged 21 to 70 diagnosed with major depressive disorder.
  • First depressive episode before age 45.
  • Tried at least four treatments in current episode of depression with unsatisfactory results.
  • Taken medications such as Zoloft®, Prozac®, Lexapro®, Wellbutrin®, Paxil®, Effexor®, Cymbalta®, and combinations of these or other medications.
  • Participated in psychotherapy, cognitive behavioral therapy (CBT), or other talk therapies.
  • Have tried Vagus nerve stimulation (VNS) or transcranial magnetic stimulation (TMS or rTMS). Have tried Electroconvulsive therapy (ECT).
  • Are open to considering a surgical option for your depression.

Study-related evaluations at no cost. Compensation provided.

*Caution: Investigational device. Limited by United States law to investigational use.
Contact Chelsea 508-856-5312.
http://www.umassmed.edu/psychopharm/research.aspx

Docket # H-13482


National Institute of Mental Health (NIMH) 

Sustaining Remission of Psychotic Depression Study

  • For patients who are currently suffering from depression with irrational worries.
  • 21 to 85 years of age and experiencing symptoms of depression with irrational worries.
  • Cannot be pregnant.

Study-related evaluations and medications at no cost. Compensation provided.

Contact Chelsea Kosma @ 508-856-5312
http://www.umassmed.edu/psychopharm/research.aspx

Docket # H-14207

▴ Back To Top
Section Menu To Top